- Home
- ELTX vs VGI Comparison
ELTX vs VGI Comparison
Compare ELTX & VGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELTX
- VGI
- Stock Information
- Founded
- ELTX 2011
- VGI 2012
- Country
- ELTX United States
- VGI United States
- Employees
- ELTX N/A
- VGI N/A
- Industry
- ELTX Biotechnology: Pharmaceutical Preparations
- VGI Investment Managers
- Sector
- ELTX Health Care
- VGI Finance
- Exchange
- ELTX Nasdaq
- VGI Nasdaq
- Market Cap
- ELTX 121.7M
- VGI N/A
- IPO Year
- ELTX N/A
- VGI N/A
- Fundamental
- Price
- ELTX $8.09
- VGI $7.80
- Analyst Decision
- ELTX Strong Buy
- VGI
- Analyst Count
- ELTX 2
- VGI 0
- Target Price
- ELTX $9.50
- VGI N/A
- AVG Volume (30 Days)
- ELTX 48.3K
- VGI 46.0K
- Earning Date
- ELTX 08-12-2025
- VGI 01-01-0001
- Dividend Yield
- ELTX N/A
- VGI 12.66%
- EPS Growth
- ELTX N/A
- VGI N/A
- EPS
- ELTX N/A
- VGI N/A
- Revenue
- ELTX N/A
- VGI N/A
- Revenue This Year
- ELTX N/A
- VGI N/A
- Revenue Next Year
- ELTX N/A
- VGI N/A
- P/E Ratio
- ELTX N/A
- VGI N/A
- Revenue Growth
- ELTX N/A
- VGI N/A
- 52 Week Low
- ELTX $3.70
- VGI $6.68
- 52 Week High
- ELTX $9.99
- VGI $7.99
- Technical
- Relative Strength Index (RSI)
- ELTX 62.14
- VGI 51.62
- Support Level
- ELTX $7.76
- VGI $7.82
- Resistance Level
- ELTX $8.94
- VGI $7.93
- Average True Range (ATR)
- ELTX 0.37
- VGI 0.06
- MACD
- ELTX -0.03
- VGI -0.00
- Stochastic Oscillator
- ELTX 51.09
- VGI 39.29
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.